Q-omics provides the consensus-scored MIR548J profile across patient tissues and cancer cell-line models. MIR548J expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR548J is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR548J RNA expression shows 7,903 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, BRCA, and LAML as cancer lineages where MIR548J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548J survival associations across molecular data types. MIR548J RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548J RNA expression–survival associations across cancer types. High MIR548J expression shows unfavorable associations in MESO, THCA, CESC, CHOL and LIHC, but favorable associations in OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR548J RNA expression.
This table summarizes MIR548J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548J shows higher tumor expression in BRCA and KICH. The BRCA box plot shows higher MIR548J RNA expression in tumor versus normal tissue (log2 FC = +0.161, t-test p = .019).
This table shows molecular features associated with MIR548J in patient tissues and cancer cell lines. In patient samples, MIR548J shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
